• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Sorafenib in combination with transarterial chemoembolization for the treatment of hepatocellular carcinoma.

作者信息

Geschwind Jean-Francois H, Chapiro Julius

机构信息

Yale School of Medicine, New Haven, Connecticut.

出版信息

Clin Adv Hematol Oncol. 2016 Aug;14(8):585-7.

PMID:27487101
Abstract
摘要

相似文献

1
Sorafenib in combination with transarterial chemoembolization for the treatment of hepatocellular carcinoma.索拉非尼联合经动脉化疗栓塞术治疗肝细胞癌。
Clin Adv Hematol Oncol. 2016 Aug;14(8):585-7.
2
Transarterial chemoembolization and sorafenib in patients with intermediate-stage hepatocellular carcinoma: time to enter routine clinical practice?经动脉化疗栓塞术与索拉非尼治疗中期肝细胞癌患者：是时候进入常规临床实践了吗？
Future Oncol. 2015;11(17):2371-3. doi: 10.2217/FON.15.173. Epub 2015 Aug 13.
3
Treatment of intermediate-stage hepatocellular carcinoma.中期肝细胞癌的治疗
Clin Adv Hematol Oncol. 2015 Aug;13(8):501-3.
4
Multicenter Phase II Clinical Trial of Sorafenib Combined with Transarterial Chemoembolization for Advanced Stage Hepatocellular Carcinomas (Barcelona Clinic Liver Cancer Stage C): STAB Study.索拉非尼联合经动脉化疗栓塞治疗晚期肝细胞癌（巴塞罗那临床肝癌分期C期）的多中心II期临床试验：STAB研究
J Vasc Interv Radiol. 2018 Aug;29(8):1061-1067. doi: 10.1016/j.jvir.2018.03.020. Epub 2018 Jun 20.
5
Transarterial chemoembolization and sorafenib in hepatocellular carcinoma.经动脉化疗栓塞术与索拉非尼治疗肝细胞癌
Expert Rev Anticancer Ther. 2014 Jul;14(7):831-45. doi: 10.1586/14737140.2014.920694. Epub 2014 May 22.
6
Transarterial chemoembolization combined with sorafenib for unresectable hepatocellular carcinoma: a systematic review and meta-analysis.经动脉化疗栓塞联合索拉非尼治疗不可切除肝细胞癌：一项系统评价与Meta分析
Mol Biol Rep. 2014 Oct;41(10):6575-82. doi: 10.1007/s11033-014-3541-7. Epub 2014 Aug 5.
7
Interim analysis of START: Study in Asia of the combination of TACE (transcatheter arterial chemoembolization) with sorafenib in patients with hepatocellular carcinoma trial.START：研究经导管动脉化疗栓塞（TACE）联合索拉非尼治疗肝细胞癌的亚洲临床试验中期分析。
Int J Cancer. 2013 May 15;132(10):2448-58. doi: 10.1002/ijc.27925. Epub 2012 Nov 28.
8
Sorafenib combined with transarterial chemoembolization versus transarterial chemoembolization alone for advanced-stage hepatocellular carcinoma: a propensity score matching study.索拉非尼联合经动脉化疗栓塞术与单纯经动脉化疗栓塞术治疗晚期肝细胞癌的倾向评分匹配研究
PLoS One. 2014 May 9;9(5):e96620. doi: 10.1371/journal.pone.0096620. eCollection 2014.
9
Retrospective analysis of transarterial chemoembolization and sorafenib in Chinese patients with unresectable and recurrent hepatocellular carcinoma.中国不可切除及复发性肝细胞癌患者经动脉化疗栓塞术与索拉非尼的回顾性分析
Oncotarget. 2016 Dec 13;7(50):83806-83816. doi: 10.18632/oncotarget.11514.
10
The Impact of Combined Transarterial Chemoembolization on the Overall Survival of Patients with Advanced Hepatocellular Carcinoma Treated with Sorafenib.经动脉化疗栓塞联合治疗对接受索拉非尼治疗的晚期肝细胞癌患者总生存期的影响。
Hepatogastroenterology. 2014 May;61(131):802-8.

引用本文的文献

1
Janus Microcarriers for Magnetic Field-controlled Combination Chemotherapy of Hepatocellular Carcinoma.用于肝癌磁场控制联合化疗的Janus微载体
Adv Funct Mater. 2019 Jun 27;29(26). doi: 10.1002/adfm.201901384. Epub 2019 Apr 30.
2
The Influence of Additional Treatments on the Survival of Patients Undergoing Transarterial Radioembolization (TARE).额外治疗对接受经动脉放射性栓塞术（TARE）治疗的患者生存的影响。
Curr Oncol. 2024 Mar 13;31(3):1504-1514. doi: 10.3390/curroncol31030114.
3
Preclinical Therapeutic Evaluation of Lenvatinib-Eluting Microspheres for Transcatheter Arterial Chemoembolization of Hepatocellular Carcinoma.
经导管动脉化疗栓塞治疗肝细胞癌用仑伐替尼载药微球的临床前治疗评估。
Cardiovasc Intervent Radiol. 2022 Dec;45(12):1834-1841. doi: 10.1007/s00270-022-03242-8. Epub 2022 Aug 12.
4
Sorafenib inhibits ovarian cancer cell proliferation and mobility and induces radiosensitivity by targeting the tumor cell epithelial-mesenchymal transition.索拉非尼通过靶向肿瘤细胞上皮-间质转化来抑制卵巢癌细胞的增殖和迁移，并诱导放射敏感性。
Open Life Sci. 2022 Jun 15;17(1):616-625. doi: 10.1515/biol-2022-0066. eCollection 2022.
5
Sorafenib inhibits tumor cell growth and angiogenesis in canine transitional cell carcinoma.索拉非尼抑制犬膀胱移行细胞癌肿瘤细胞生长和血管生成。
J Vet Med Sci. 2022 May 17;84(5):666-674. doi: 10.1292/jvms.21-0478. Epub 2022 Apr 5.
6
Optimal timing of combining sorafenib with trans-arterial chemoembolization in patients with hepatocellular carcinoma: A meta-analysis.索拉非尼与经动脉化疗栓塞术联合应用于肝细胞癌患者的最佳时机：一项荟萃分析。
Transl Oncol. 2021 Dec;14(12):101238. doi: 10.1016/j.tranon.2021.101238. Epub 2021 Oct 7.
7
Locoregional and systemic therapy for hepatocellular carcinoma.肝细胞癌的局部区域和全身治疗
J Gastrointest Oncol. 2017 Apr;8(2):215-228. doi: 10.21037/jgo.2017.03.13.